GSK starts Phase III flu study; Deltex permanently shuts its doors;

 @FierceBiotech: Feds' $1B antiterror drug development program yields little. News | Follow @FierceBiotech

 @JohnCFierce: Ariad shares shot up 36 percent on sarcoma data. Three weeks isn't much time, but deadly cancers have their own metric for success. | Follow @JohnCFierce 

> Preparing for future flu seasons, GlaxoSmithKline has started a Phase III study pitting its zanamivir, an intravenous version of the inhalable Relenza, against Roche's oral flu treatment Tamiflu. Report

> After multiple cGMP violations, the FDA has ordered Deltex Pharmaceuticals to permanently halt its operations and recall all products distributed after Oct. 2008. According to the FDA, Deltex also has been producing unapproved products. News

> Researchers at the Technion-Israel Institute of Technology in Haifa have come up with a way to separate enough protein biomarkers to diagnose blood cancers, including leukemias and multiple myelomas. Article

> Amgen has sold its 10,000 sq. ft. manufacturing and development facility in Fremont, CA to Boehringer Ingelheim. Amgen's spokeswoman Mary Klem said that most, if not all, of the 360 employees based there should receive offers from Boehringer in the next month. Financial terms of the deal were not disclosed. Story

> Researchers at Massachusetts General Hospital Cancer Center might have identified a new biomarker for cancer. Writing in the journal Science, the team discovered a previously unknown feature of common tumor cells--massive overexpression of certain DNA sequences that do not code for proteins. These DNA sequences--called satellite repeats--had never previously been a suspect in cancers. Report

> The U.S. National Cancer Institute will sponsor a study of Oncolytics Biotech's cancer drug Reolysin. The drug will be studied as apotential therapy for pancreatic cancer. It's Reolysin's fourth trial, after others have studied it for metastatic melanoma, ovarian, head and neck cancers. Article

> Derek Lowe focuses on the rewards and issues associated with biomarker research in his In The Pipeline blog. Post

And Finally... Tranexamic acid, a generic drug usually used to stem heavy menstrual bleeding, could save the lives of accident and combat victims who would otherwise bleed to death. A study published in the Cochrane Library journal, which gathered facts from a 20,000+ person study and a 240 patient study, showed that the drug saved 10 percent more severe bleeding patients than those who did not receive the drug. Article